ERASCA INC's ticker is and the CUSIP is 29479A108. A total of 120 filers reported holding ERASCA INC in Q4 2023. The put-call ratio across all filers is 1.18 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2023 | $151,959 | +8.1% | 71,342 | 0.0% | 0.00% | – |
| Q3 2023 | $140,544 | -34.6% | 71,342 | 0.0% | 0.00% | – |
| Q2 2023 | $214,740 | 0.0% | 71,342 | 0.0% | 0.00% | – |
| Q1 2023 | $214,740 | +104.2% | 71,342 | +192.3% | 0.00% | – |
| Q4 2022 | $105,181 | -99.9% | 24,404 | +27.8% | 0.00% | – |
| Q3 2022 | $148,980,000 | +40.0% | 19,100 | 0.0% | 0.00% | – |
| Q2 2022 | $106,387,000 | – | 19,100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARCH Venture Management, LLC | 11,055,554 | $95,078,000 | 13.59% |
| AH Equity Partners Bio II, L.L.C. | 2,500,000 | $21,500,000 | 12.39% |
| Cormorant Asset Management, LP | 10,505,554 | $90,348,000 | 6.94% |
| EDBI Pte Ltd | 888,888 | $7,644,000 | 5.09% |
| AH Equity Partners LSV II, L.L.C. | 312,500 | $2,688,000 | 1.94% |
| PFM Health Sciences, LP | 4,791,406 | $41,206,000 | 1.54% |
| Artal Group S.A. | 3,172,221 | $27,281,000 | 1.14% |
| AH Equity Partners V, L.L.C. | 50,000 | $430,000 | 1.02% |
| Orbimed Advisors | 1,667,693 | $14,342,000 | 0.23% |
| EcoR1 Capital, LLC | 678,441 | $5,835,000 | 0.18% |